- Home
- Articles
- us virgislands
- biopharmaceutical development
Refine by
Biopharmaceutical Development Articles & Analysis
11 articles found
In modern biopharmaceutical manufacturing, downstream processing development has become one of the most critical and resource-intensive stages. ...
Recombinant protein expression is a cornerstone of modern biopharmaceutical development, providing the means to produce proteins with therapeutic potential, enzymes, and antibodies. ...
Compared to protein drugs, peptide drugs also have advantages such as good stability, high purity, low production cost, and low immunogenicity. With the rapid development and maturity of peptide synthesis technology, peptide drugs have become the focus of biopharmaceutical research and development in recent years. ...
Bioproduction is a critical element in the creation of many vaccines, therapeutics, and other biopharmaceuticals. A central facet of this process involves the development of stable cell lines that are capable of producing these vital products in abundance and with consistency. ...
Host cell proteins (HCPs) are process-related impurities produced by host cells and are typically present at low levels in recombinant biopharmaceutical products. Enzyme-linked immunosorbent assay (ELISA) has traditionally been used to monitor the total content of HCP in the production of therapeutic protein drugs. ...
Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. ...
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics. ...
As regulators focus in on the critical quality attributes (CQAs) of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations assays – other than to run additional orthogonal assays? ...
Due to the failure of the regulatory framework and applied sciences to keep pace with advances in discovery, there is a bottleneck in the development phase of R&D. While improved process may help, there are still problems related to the products themselves, such as the need to move from a population-based model of product development, in which one size fits all, ...
Risk is a characteristic of innovative industries. The process of new product development in the biopharmaceutical sector is extremely dynamic and unpredictable, creating both risks and opportunities for the small and medium-sized enterprises. ...
This paper analyses which organisational and industrial factors influence the chance that a US biopharmaceutical start-up is able to introduce a new drug on the US market. ...